Cargando…

Oestradiol measurement during fulvestrant treatment for breast cancer

Biochemical evaluation of menopausal status is used to inform treatment decisions, including clinical trial eligibility in women with oestrogen receptor positive breast cancer. However, fulvestrant may interfere with oestradiol immunoassays and confound accurate assessment in this context. We conduc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Owen, Laura J., Monaghan, Phillip J., Armstrong, Anne, Keevil, Brian G., Higham, Claire, Salih, Zena, Howell, Sacha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461991/ https://www.ncbi.nlm.nih.gov/pubmed/30679781 http://dx.doi.org/10.1038/s41416-019-0378-9

Ejemplares similares

Deficits in plasma oestradiol measurement in studies and management of breast cancer
por: Dowsett, Mitch, et al.
Publicado: (2005)

Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2021)

Increased risk of breast cancer in neurofibromatosis type 1: current insights
por: Howell, Sacha J, et al.
Publicado: (2017)

Serum oestradiol in women with and without breast disease.
por: Bennett, I. C., et al.
Publicado: (1990)

Oestradiol-17β plasma concentrations after intramuscular injection of oestradiol benzoate or oestradiol cypionate in llamas (Lama glama)
por: Cavilla, María V, et al.
Publicado: (2010)

A Review of Fulvestrant in Breast Cancer
por: Nathan, Mark R., et al.
Publicado: (2017)

Measurement of oestradiol receptors by five institutions on common tissue samples.
por: King, R. J., et al.
Publicado: (1978)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

In vivo uptake of labelled oestradiol by benign and malignant tumours of the human breast.
por: O'Higgins, N. J., et al.
Publicado: (1973)

SAT-741 Salivary Cortisol and Cortisone Measurement Provide a Novel and Non-Invasive Method of Monitoring Medical Therapy in Cushing’s Syndrome
por: Manson, Megan Elizabeth, et al.
Publicado: (2020)

Fulvestrant: pharmacokinetics and pharmacology
por: Robertson, J F R, et al.
Publicado: (2004)

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
por: Schmid, Peter, et al.
Publicado: (2019)

Oestradiol Receptors in Carcinoma and Benign Disease of the Breast: An In Vitro Assay
por: Feherty, Patricia, et al.
Publicado: (1971)

Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant
por: Kut, Engin, et al.
Publicado: (2023)

ɶstradiol Benzoate Therapy in Senile Vaginitis
por: Macgregor, T. N.
Publicado: (1938)

Oestradiol synthesis from C19 steroids by human breast cancers.
por: Miller, W. R., et al.
Publicado: (1976)

Serum Oestradiol-17β in Women with Benign and Malignant Breast Disease
por: England, P. C., et al.
Publicado: (1974)

Fulvestrant and the sequential endocrine cascade for advanced breast cancer
por: Johnston, S
Publicado: (2004)

Breast density quantitative measures and breast cancer risk among screened Black women
por: Mahmoud, Mattia A, et al.
Publicado: (2023)

Non-protein bound oestradiol, sex hormone binding globulin, breast cancer and breast cancer risk.
por: Bruning, P. F., et al.
Publicado: (1985)

Serum Oestradiol-17β in Normal Women
por: England, P. C., et al.
Publicado: (1974)

Fulvestrant in advanced breast cancer: evidence to date and place in therapy
por: Boér, Katalin
Publicado: (2017)

Synchronous onset of oestradiol-17β secretion by Meishan conceptuses
por: Pickard, Amanda R, et al.
Publicado: (2003)

Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines.
por: Lykkesfeldt, A. E., et al.
Publicado: (1986)

A method to detect fulvestrant interference in estradiol in breast cancer patients
por: Brito, Margarida, et al.
Publicado: (2023)

The effect of priming and duration of oestradiol benzoate treatment before progesterone administration on embryo development and survival in anestrous recipient mares
por: Oquendo, Pedro S., et al.
Publicado: (2022)

Quantification of oestradiol binding at the surface of human lymphocytes by flow cytofluorimetry.
por: Tubiana, N., et al.
Publicado: (1986)

Biosynthesis of 17beta-oestradiol in human breast carcinoma tissue and a novel method for its characterization.
por: Adams, J. B., et al.
Publicado: (1975)

Endogenous oestradiol and progesterone as predictors of oncogenic human papillomavirus (HPV) persistence
por: Fischer, Susanne, et al.
Publicado: (2022)

CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis
por: Behrouzi, Roya, et al.
Publicado: (2023)

Fulvestrant-induced toxic epidermal necrolysis
por: Morales-Conde, Macarena, et al.
Publicado: (2019)

Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer
por: Yoshimura, Noriko, et al.
Publicado: (2004)

A developmental sex difference in hippocampal neurogenesis is mediated by endogenous oestradiol
por: Bowers, J Michael, et al.
Publicado: (2010)

The Exposure of Breast Cancer Cells to Fulvestrant and Tamoxifen Modulates Cell Migration Differently
por: Lymperatou, Dionysia, et al.
Publicado: (2013)

Oestradiol-17 beta and prolactin levels in rat peripheral plasma.
por: Hawkins, R. A., et al.
Publicado: (1975)

Oestradiol synthesized by female neurons generates sex differences in neuritogenesis
por: Ruiz-Palmero, Isabel, et al.
Publicado: (2016)

Blocking oestradiol synthesis pathways with potent and selective coumarin derivatives
por: Niinivehmas, Sanna, et al.
Publicado: (2018)

Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer
por: Liu, Qi, et al.
Publicado: (2023)

Palbociclib and Fulvestrant Act in Synergy to Modulate Central Carbon Metabolism in Breast Cancer Cells
por: Warth, Benedikt, et al.
Publicado: (2019)

Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden
por: Sabale, Ugne, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6rn4kkrvr49hukioal9s6p1cnd